Chemogenetic Control of Striatal Astrocytes Improves Parkinsonian Motor Deficits in Mice
Glia · 2025-06 · 73 (6) · 1188-1202
DOI: 10.1002/glia.24679 ↗Kurz gefasst
Fachartikel in der Zeitschrift Glia, online erschienen am 04.02.2025. Verfasst von Wesley R Evans und 7 weiteren Autor:innen. Beteiligte Einrichtung: WM Keck Center for Collaborative Neuroscience, Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey, USA. Hauptthemen laut MEDLINE: Astrocytes, Corpus Striatum, Parkinsonian Disorders. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Parkinson's Foundation, NIGMS NIH HHS, NIAAA NIH HHS.
Abstract (Originalsprache)
Parkinson's disease (PD) is characterized by the degeneration of dopaminergic nigrostriatal inputs, which causes striatal network dysfunction and leads to pronounced motor deficits. Recent evidence highlights astrocytes as a potential local source for striatal neuromodulation. There is substantial evidence for norepinephrine‐mediated recruitment of cortical astrocyte activity during movement and locomotion. However, it is unclear how astrocytes in the striatum, a region devoid of norepinephrine neuromodulatory inputs, respond during locomotion. Moreover, it remains unknown how dopamine loss affects striatal astrocyte activity and whether astrocyte activity regulates behavioral deficits in PD. We addressed these questions by performing astrocyte‐specific calcium recordings and manipulations using in vivo fiber photometry and chemogenetics. We find that locomotion elicits astrocyte calcium activity over a slower timescale than neurons. Acute pharmacological blockade of dopamine receptors only moderately reduced locomotion‐related astrocyte activity. Yet, unilateral dopamine depletion significantly attenuated astrocyte calcium responses. Chemogenetic stimulation of G i ‐coupled receptors partially improved this functional astrocyte deficit in dopamine‐lesioned mice. In parallel, chemogenetic manipulation restored asymmetrical motor deficits and moderately improved open‐field exploratory behavior. Together, our results establish a novel role for functional striatal astrocyte signaling in modulating motor function in PD and highlight non‐neuronal targets for potential PD therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- WM Keck Center for Collaborative Neuroscience, Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey, USA.
ORCID-Profile: Rafiq Huda
Förderung
- Parkinson's Foundation
- NIGMS NIH HHS
- NIAAA NIH HHS
- American Parkinson Disease Association
- NIMH NIH HHS
- Brain Research Foundation
- National Institute of General Medical Sciences
- National Institute on Alcohol Abuse and Alcoholism
Zitieren
APA
Evans, W. R., Baskar, S. S., Vellore, A., Costa, A. R. C. E., Jacob, C., Ravoori, S., Arigbe, A., & Huda, R. (2025). Chemogenetic Control of Striatal Astrocytes Improves Parkinsonian Motor Deficits in Mice. Glia, 73(6), 1188-1202. https://doi.org/10.1002/glia.24679
Vancouver
Evans WR, Baskar SS, Vellore A, Costa ARCE, Jacob C, Ravoori S, et al. Chemogenetic Control of Striatal Astrocytes Improves Parkinsonian Motor Deficits in Mice. Glia. 2025;73(6):1188-1202. doi:10.1002/glia.24679
BibTeX
@article{Evans2025,
author = {Evans, Wesley R and Baskar, Sindhuja S and Vellore, Angelica and Costa, Ana Raquel Castro E and Jacob, Cynthia and Ravoori, Sanya and Arigbe, Abimbola and Huda, Rafiq},
title = {Chemogenetic Control of Striatal Astrocytes Improves Parkinsonian Motor Deficits in Mice},
journal = {Glia},
year = {2025},
volume = {73},
number = {6},
pages = {1188--1202},
doi = {10.1002/glia.24679}
}
EUVIMED